{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:17:49Z","timestamp":1790075869061,"version":"4.0.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this article is to assess the risk and potential mechanisms of cardiovascular adverse events in patients treated with nilotinib or imatinib by conducting a systematic review, meta-analysis and integrative bioinformatics analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Three databases were systematically searched for studies published from inception to May 29, 2022. Differential expression analysis and weighted gene coexpression network analysis (WGCNA) were performed to search for modules of genes most associated with cardiotoxicity. Protein-protein interaction (PPI) network analysis was then performed to identify hub genes for the cardiotoxicity of nilotinib. Molecular docking was used to analyze the effects of rosuvastatin and aspirin on these targets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients treated with nilotinib as first-line treatment were associated with a higher risk of CAE (OR = 3.43 [95% CI 2.77\u20134.25]), CAD (OR = 5.30 [95% CI 3.85\u20137.29]), ACS (OR 2.7 [95% CI 1.60\u20134.54]), CVA (OR 5.76 [95% CI 2.84\u201311.28]), PAOD (OR 5.57 [95% CI 3.26\u20139.50]) and arrhythmia (OR 2.34 [1.17,4.67]) than those treated with imatinib, while no significant difference was found in the risk of HF (OR 1.40 [95% CI 0.42\u20134.69]) between the two groups. Patients who were treated with more than 600 mg daily dosage of nilotinib or followed up for more than 5 years had a higher risk of ACS and CVA. IL6, CXCL8, CCL2, SOD2, NFKBIA, and BIRC3 were identified as the top 6 hub genes in the magenta module (human cardiomyocyte samples) and were mainly enriched in the NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, lipid and atherosclerosis signaling pathway. TYROBP and CSF1R were identified as hub genes in the turquoise module (liver samples from Mus musculus). GSEA results showed that type II diabetes mellitus, B-cell receptor, apoptosis, insulin, natural killer cell mediated cytotoxicity,<\/jats:p><jats:p>mTOR, chemokine, and T-cell receptor signaling pathways were related to the higher risk of atherosclerosis caused by nilotinib. Rosuvastatin can effectively bind to most of the hub targets and proteins enriched in the inflammatory pathways above.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CML patients who start with nilotinib have a higher risk of CAE than those with imatinib. Atherosclerosis caused by the inflammatory response and glycolipid metabolism disorder is the key mechanism of nilotinib cardiotoxicity. Rosuvastatin may be an effective treatment for the cardiotoxicity of nilotinib.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.966182","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T04:40:56Z","timestamp":1667882456000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Sicong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinshan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.849175","article-title":"Alteration of N6-Methyladenosine mRNA methylation in a human stem cell-derived cardiomyocyte model of tyrosine kinase inhibitor-induced cardiotoxicity.","volume":"23","author":"Ma","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell."},{"key":"B4","doi-asserted-by":"publisher","first-page":"D362","DOI":"10.1093\/nar\/gkw937","article-title":"The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible.","volume":"45","author":"Szklarczyk","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12185-021-03216-5","article-title":"Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial.","volume":"115","author":"Nakamae","year":"2022","journal-title":"Int J Hematol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.675811","article-title":"Cardiovascular issues in tyrosine kinase inhibitors treatments for chronic myeloid leukemia: a review.","volume":"12","author":"Santoro","year":"2021","journal-title":"Front Physiol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.20165","article-title":"Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis.","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open."},{"key":"B8","doi-asserted-by":"publisher","first-page":"E342","DOI":"10.1002\/ajh.25232","article-title":"Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.","volume":"93","author":"Racil","year":"2018","journal-title":"Am J Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000505486","article-title":"Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: a real-world single-center experience.","volume":"98","author":"Novo","year":"2020","journal-title":"Oncology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007183","article-title":"Recommendations and associated levels of evidence for statin use in primary prevention of cardiovascular disease: a comparison at population level of the American Heart Association\/American College of Cardiology\/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs\/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology\/European Atherosclerosis Society Clinical Practice Guidelines.","volume":"14","author":"Pavlovi\u0107","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009745","article-title":"Association between statin use and cardiovascular events after carotid artery revascularization.","volume":"7","author":"Hussain","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3987065","article-title":"Comparative lipid-lowering\/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials.","volume":"2020","author":"Zhang","year":"2020","journal-title":"Cardiovasc Ther."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067731","article-title":"Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis.","volume":"376","author":"Hodkinson","year":"2022","journal-title":"BMJ."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18396-7","article-title":"Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity.","volume":"11","author":"van Hasselt","year":"2020","journal-title":"Nat Commun."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-13-","article-title":"Unlocking the potential of publicly available microarray data using inSilicoDb and inSilicoMerging R\/Bioconductor packages.","volume":"13","author":"Taminau","year":"2012","journal-title":"BMC Bioinformatics."},{"key":"B19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods.","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2018.00055","article-title":"The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model.","volume":"5","author":"Pouwer","year":"2018","journal-title":"Front Cardiovasc Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: a web server for functional enrichment analysis and functional annotation of gene lists.","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1093\/bioinformatics\/btab319","article-title":"IntAct App: a Cytoscape application for molecular interaction network visualization and analysis.","volume":"37","author":"Ragueneau","year":"2021","journal-title":"Bioinformatics."},{"key":"B23","doi-asserted-by":"publisher","first-page":"D183","DOI":"10.1093\/nar\/gkab1092","article-title":"LncACTdb 3.0: an updated database of experimentally supported ceRNA interactions and personalized networks contributing to precision medicine.","volume":"50","author":"Wang","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02728-2","article-title":"Correction to: Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis.","volume":"19","author":"Zhao","year":"2021","journal-title":"J Transl Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.","volume":"125","author":"Wang","year":"2015","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.835563","article-title":"Pro-Inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: results of a prospective multicenter front-line TKIs study (KIARO Study).","volume":"12","author":"Sicuranza","year":"2022","journal-title":"Front Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00277-018-3412-8","article-title":"Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML cooperative study group database.","volume":"97","author":"Fujioka","year":"2018","journal-title":"Ann Hematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ajh.26463","article-title":"Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.","volume":"97","author":"Dahl\u00e9n","year":"2022","journal-title":"Am J Hematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4149\/BLL_2021_085","article-title":"Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.","volume":"122","author":"Petrikova","year":"2021","journal-title":"Bratisl Lek Listy."},{"key":"B33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study.","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/onco.13944","article-title":"Tyrosine kinase inhibitors and vascular adverse events in patients with chronic myeloid leukemia: a population-based, propensity score-matched cohort study.","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist."},{"key":"B35","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"key":"B36","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","article-title":"Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.","volume":"109","author":"Kizaki","year":"2019","journal-title":"Int J Hematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or nontyrosine kinase therapy: a retrospective cohort analysis.","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab043","article-title":"Cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study.","volume":"28","author":"Yang","year":"2021","journal-title":"Eur J Prev Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia."},{"key":"B40","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40261-018-0676-7","article-title":"Pattern of use and long-term safety of tyrosine kinase inhibitors: a decade of real-world management of chronic myeloid leukemia.","volume":"38","author":"Bettiol","year":"2018","journal-title":"Clin Drug Investig."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4246703","article-title":"Candidate biomarkers and molecular mechanism investigation for glioblastoma multiforme utilizing WGCNA.","volume":"2018","author":"Yang","year":"2018","journal-title":"Biomed Res Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s00277-020-04392-w","article-title":"Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.","volume":"100","author":"Caocci","year":"2021","journal-title":"Ann Hematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.tips.2022.06.009","article-title":"Mouse models of atherosclerosis in translational research.","volume":"43","author":"Ilyas","year":"2022","journal-title":"Trends Pharmacol Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/s41375-018-0337-0","article-title":"Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts.","volume":"33","author":"Sadiq","year":"2019","journal-title":"Leukemia."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1210\/jc.2010-0086","article-title":"Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?","volume":"95","author":"Fitter","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/nu10081024","article-title":"Paeoniflorin ameliorates fructose-induced insulin resistance and hepatic steatosis by activating LKB1\/AMPK and AKT Pathways.","volume":"10","author":"Li","year":"2018","journal-title":"Nutrients."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.4161\/15384101.2014.947750","article-title":"Insulin resistance in the liver: deficiency or excess of insulin?","volume":"13","author":"Bazotte","year":"2014","journal-title":"Cell Cycle."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.bbadis.2018.06.011","article-title":"Combating cellular senescence by sirtuins: implications for atherosclerosis.","volume":"1865","author":"Ma","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-3-030-73234-9_11","article-title":"The role of chemokines in cardiovascular diseases and the therapeutic effect of curcumin on CXCL8 and CCL2 as pathological chemokines in atherosclerosis.","volume":"1328","author":"Hedayati-Moghadam","year":"2021","journal-title":"Adv Exp Med Biol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119378","article-title":"Optical\/MRI dual-modality imaging of M1 macrophage polarization in atherosclerotic plaque with MARCO-targeted upconversion luminescence probe.","volume":"219","author":"Wang","year":"2019","journal-title":"Biomaterials."},{"key":"B51","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease.","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J Cell Physiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.plipres.2011.04.002","article-title":"Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy.","volume":"50","author":"McLaren","year":"2011","journal-title":"Prog Lipid Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10741-018-09764-z","article-title":"Curcumin as a potential modulator of M1 and M2 macrophages: new insights in atherosclerosis therapy.","volume":"24","author":"Momtazi-Borojeni","year":"2019","journal-title":"Heart Fail Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/glia.22802","article-title":"DAP12-dependent signal promotes pro-inflammatory polarization in microglia following nerve injury and exacerbates degeneration of injured neurons.","volume":"63","author":"Kobayashi","year":"2015","journal-title":"Glia."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.602908","article-title":"Identifying RBM47, HCK, CD53, TYROBP, and HAVCR2 as hub genes in advanced atherosclerotic plaques by network-based analysis and validation.","volume":"11","author":"Liu","year":"2021","journal-title":"Front Genet."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.5551\/jat.52993","article-title":"IGFBP6 is downregulated in unstable carotid atherosclerotic plaques according to an integrated bioinformatics analysis and experimental verification.","volume":"27","author":"Liu","year":"2020","journal-title":"J Atheroscler Thromb."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.13436","article-title":"Identification of key differential genes in intimal hyperplasia induced by left carotid artery ligation.","volume":"10","author":"Zhang","year":"2022","journal-title":"PeerJ."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4026604","article-title":"Comprehensive analysis to identify key genes involved in advanced atherosclerosis.","volume":"2021","author":"Huo","year":"2021","journal-title":"Dis Markers."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250442","article-title":"Effects of imatinib on vascular insulin sensitivity and free fatty acid transport in early weight gain.","volume":"16","author":"Box","year":"2021","journal-title":"PLoS One."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32853-w","article-title":"Imatinib reduces nonalcoholic fatty liver disease in obese mice by targeting inflammatory and lipogenic pathways in macrophages and liver.","volume":"8","author":"AlAsfoor","year":"2018","journal-title":"Sci Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1080\/10428194.2022.2068003","article-title":"Effects of imatinib on glycemic and lipid profiles: a retrospective cohort study.","volume":"63","author":"Markovits","year":"2022","journal-title":"Leuk Lymphoma."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020804","article-title":"Inflammatory burden and immunomodulative therapeutics of cardiovascular diseases.","volume":"23","author":"Kao","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-020-01604-z","article-title":"Anti-inflammatory effects of rosuvastatin treatment on coronary artery ectasia patients of different age groups.","volume":"20","author":"Fan","year":"2020","journal-title":"BMC Cardiovasc Disord."},{"key":"B64","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","article-title":"Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways.","volume":"60","author":"Koushki","year":"2021","journal-title":"Clin Rev Allergy Immunol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.966182\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T04:40:59Z","timestamp":1667882459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.966182\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":64,"alternative-id":["10.3389\/fcvm.2022.966182"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.966182","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"article-number":"966182"}}